24-Hour Parkinson’s Drug Cuts Symptoms
Longer-Acting Requip May Reduce Need for Levodopa
April 4, 2007 -- A new 24-hour form of the Parkinson’s drug Requip may
provide longer-lasting relief from symptoms and reduce the need for other drugs
to control the disease.
A new study shows the longer-acting version of Requip reduced by more than
two hours the daily “off time” Parkinson’s patients experience as their drugs
wear off and symptoms return.
In addition, people who took the 24-hour Requip were also able to reduce
their daily dose of the widely used Parkinson’s drug levodopa, which is
commonly used to treat the disease.
“[Requip] 24-hour prolonged release, when taken with levodopa, is effective
in reducing daily ‘off time’ for Parkinson’s patients who aren’t getting the
best results from levodopa,” says researchers Rajesh Pahwa, MD, of the
University of Kansas Medical Center in Kansas City, Kan., in a news release.
“We also found the drug helped improve quality of life and motor function.”
Longer-Acting Parkinson’s Drug
In the study, published in Neurology, researchers examined the
effects of the new 24-hour formulation of Requip in 393 people with Parkinson’s
disease who weren’t responding well to levodopa alone.
Half of the patients took the prolonged-release Requip in addition to
levodopa and the other half took levodopa and a placebo for 24 weeks. Any other
Parkinson’s drugs that the patients were taking were not changed.
The results showed that the average daily ‘off time’ was reduced by an
average of 2.1 hours among those taking 24-hour Requip compared with a
reduction of only 0.3 hours among those taking the placebo. Patients taking
Requip also reduced their daily dose of levodopa by an average of 278
Those who took 24-hour Requip experienced significant improvements in
Parkinson’s disease symptoms, quality of life, depression, emotional
well-being, stigma, and sleep.
For example, researchers found the Parkinson’s disease symptoms of 42% of
those taking Requip were "much improved" or "very much
improved" compared with only 14% of the placebo group.
Side effects of Requip included involuntary movements, nausea, dizziness,
drowsiness, hallucinations, and sudden drops in blood pressure with change in
The study was supported by GlaxoSmithKline and Skye Pharma, makers of
prolonged-release Requip. GlaxoSmithKline is a WebMD sponsor.